title: [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
abstract: OBJECTIVE
  This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Thirty-two consecutive patients treated with icotinib and 33 consecutive patients treated with standard second-line chemotherapy in Xuanwu Hospital from January 2012 to July 2013 were enrolled in our retrospective research. The Response Evaluation Criteria in Solid Tumors were used to evaluate the tumor responses, and the progression-free survival (PFS) was evaluated by Kaplan-Meier method.
  
  
  RESULTS
  Icotinib was comparable with standard second-line chemotherapy for advanced NSCLC in terms of overall response rate (ORR) (28.1% vs 18.2%, P=0.341), disease control rate (DFS)(43.8% vs 45.5%, P=0.890), and PFS (4.3 months vs 3.8 months, P=0.506). In the icotinib group, the ORR of epidermal growth factor receptor (EGFR) mutant was significantly higher than that of EGFR unknown or wild type (P=0.017). In multivariate analysis, age, gender, histology, and the optimum first-line treatment response were dependent prognostic factors based on the PFS of the icotinib group. The incidence of adverse events was significantly fewer in the icotinib group than in the chemotherapy group (P=0.001).
  
  
  CONCLUSIONS
  Compared with the standard second-line chemotherapy, icotinib is active in the treatment of advanced NSCLC patients, especially with EGFR unknown in the second line, with an acceptable adverse event profile.
authors.affiliation: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
authors.forename: Shuyang
authors.initials: S
authors.lastname: Yao
authors.affiliation: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Qian
authors.affiliation: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
authors.forename: Ruotian
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
authors.forename: Yuanbo
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D043844:Crown Ethers / Q000008:administration & dosage*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib; C512478:EGFR protein, human; D066246:ErbB Receptors